Here's Why Celldex Therapeutics Stock Is Soaring Today
Shares of Celldex Therapeutics (NASDAQ: CLDX), a clinical-stage biotechnology company, are rising in response to insider stock purchases and large equity stakes acquired by independent investment firms. A stock market encouraged by the signs of confidence has driven shares 29.2% higher as of 3:42 p.m. EDT on Friday.
Shares of Celldex rose earlier this week following the presentation of results from a trial with CDX-0159 and 32 healthy patients. A single dose of CDX-1059 suppressed production of plasma tryptase, which could be a big deal for people who frequently break out in hives.
Image source: Getty Images.
Source Fool.com
